Gold bars to be exempt from tariffs, White House clarifies
Investing.com - JMP Securities raised its price target on Artivion Inc. (NYSE:AORT) to $42.00 from $33.00 on Friday, while maintaining a Market Outperform rating following the company’s second-quarter 2025 results. The stock, currently trading near its 52-week high of $33.39, has delivered a 29% return over the past year. According to InvestingPro analysis, the company’s current valuation metrics suggest it may be trading above its Fair Value.
Artivion reported quarterly results that exceeded Street expectations by approximately $5 million, representing a 5% beat. The company achieved 15% year-over-year growth (14% in constant currency) in the second quarter. With a robust current ratio of 5.53 and an overall Financial Health score rated as "GOOD" by InvestingPro, the company maintains strong liquidity positions. Discover 10+ additional exclusive ProTips and comprehensive financial metrics with InvestingPro’s detailed research report.
The strong performance was driven by continued progress in Artivion’s AMDS stent graft launch under its Humanitarian Device Exemption, with total stents improving 22% year-over-year. The company’s On-X heart valve business also showed notable gains, growing 24% compared to the same period last year.
Artivion raised its full-year sales guidance by $10 million, now projecting growth of 12-14% year-over-year in constant currency terms. This follows a first quarter where revenue increased just 2% year-over-year due to disruption from a cybersecurity event.
JMP cited the quarterly beat, raised guidance, and positive incremental product and clinical updates as key factors supporting its higher price target for the medical device company.
In other recent news, Artivion Inc. announced several developments impacting its business and financial outlook. The company is set to release its second-quarter earnings report, with expectations of 11% year-over-year growth, following a modest 2% growth in the first quarter. Stifel has increased its price target for Artivion to $36, maintaining a Buy rating, based on positive feedback from physicians using Artivion’s aortic arch dissection repair stent. Meanwhile, Citizens JMP reiterated its Market Outperform rating with a $33 price target, emphasizing anticipated sales growth acceleration in the latter half of the fiscal year.
Canaccord Genuity has initiated coverage on Artivion with a Buy rating and a $35 price target, citing strategic investments in aortic repair. Additionally, Artivion shareholders approved executive compensation and the preliminary selection of Ernst & Young LLP as the independent auditor for the fiscal year 2025. The company is also engaging in a private deal to repurchase $95 million in convertible notes, exchanging them for common stock, with the transaction expected to close by the end of May. These developments underscore Artivion’s strategic focus on financial and operational growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.